World Asset Management Inc purchased a new position in Charles River Laboratories Intl. Inc (NYSE:CRL) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,303 shares of the medical research company’s stock, valued at approximately $227,000.

A number of other institutional investors have also modified their holdings of the business. Corbett Road Capital Management LLC bought a new stake in Charles River Laboratories Intl. in the second quarter worth about $309,000. Strs Ohio raised its position in Charles River Laboratories Intl. by 41.3% in the second quarter. Strs Ohio now owns 8,515 shares of the medical research company’s stock worth $1,484,000 after acquiring an additional 2,487 shares in the last quarter. Janney Montgomery Scott LLC raised its position in Charles River Laboratories Intl. by 13.8% in the second quarter. Janney Montgomery Scott LLC now owns 26,940 shares of the medical research company’s stock worth $4,697,000 after acquiring an additional 3,270 shares in the last quarter. Creative Financial Designs Inc. ADV bought a new stake in Charles River Laboratories Intl. in the second quarter worth about $74,000. Finally, First Trust Advisors LP raised its position in Charles River Laboratories Intl. by 1.4% in the second quarter. First Trust Advisors LP now owns 586,254 shares of the medical research company’s stock worth $102,213,000 after acquiring an additional 7,955 shares in the last quarter. Hedge funds and other institutional investors own 93.25% of the company’s stock.

In related news, VP Birgit Girshick sold 780 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $165.74, for a total value of $129,277.20. Following the completion of the sale, the vice president now owns 21,837 shares of the company’s stock, valued at approximately $3,619,264.38. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO James C. Foster sold 17,446 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $162.53, for a total value of $2,835,498.38. The disclosure for this sale can be found here. In the last three months, insiders sold 22,697 shares of company stock valued at $3,744,212. 1.90% of the stock is currently owned by company insiders.

NYSE:CRL opened at $198.99 on Friday. The company has a debt-to-equity ratio of 1.49, a current ratio of 1.75 and a quick ratio of 1.51. Charles River Laboratories Intl. Inc has a fifty-two week low of $95.58 and a fifty-two week high of $203.26. The stock’s 50-day moving average is $183.54 and its two-hundred day moving average is $160.27. The stock has a market cap of $9.96 billion, a PE ratio of 40.04, a price-to-earnings-growth ratio of 2.09 and a beta of 1.19.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $1.84 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.46 by $0.38. The business had revenue of $707.06 million during the quarter, compared to analysts’ expectations of $692.11 million. Charles River Laboratories Intl. had a return on equity of 22.69% and a net margin of 9.09%. The firm’s quarterly revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 EPS. On average, equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 6.88 earnings per share for the current year.

A number of equities analysts recently weighed in on CRL shares. BofA Securities raised Charles River Laboratories Intl. from a “neutral” rating to a “buy” rating and set a $192.00 price target on the stock in a research note on Wednesday, July 1st. Robert W. Baird lifted their price target on Charles River Laboratories Intl. from $156.00 to $175.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Morgan Stanley lifted their price target on Charles River Laboratories Intl. from $152.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Citigroup lifted their price target on Charles River Laboratories Intl. from $165.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, UBS Group lifted their price target on Charles River Laboratories Intl. from $200.00 to $236.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $180.47.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: How a Strangle Strategy is different from a Straddle Strategy

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.